Crescent Biopharma (Nasdaq: CBIO) reported that the independent Compensation Committee of its Board approved equity inducement awards consisting of options to purchase an aggregate of 52,500 ordinary shares for two non-executive employees under the 2025 Employment Inducement Incentive Award Plan. The options were approved on July 22, 2026, have a 10-year term, and an exercise price of $15.83, equal to the closing price of Crescent’s shares on that date. According to Crescent Biopharma, each grant vests 25% on the first anniversary of the employee’s start date, with the remaining 75% vesting in equal monthly installments over the following three years, subject to continuous service and the terms of the Inducement Plan and individual option agreements.
Loading...
Loading translation...
Positive
None.
Negative
None.
Market reaction after inducement award grants: CBIO -4.29% in the Jul 24 session
-4.29%
10 alerts
-4.29%Session close to close
+4.4%Peak Tracked
-3.7%Trough Tracked
$615.06MMarket Cap
0.4xRel. Volume
In the Jul 24 session, CBIO declined 4.29%, reflecting a moderate negative market reaction.
Argus tracked a peak move of +4.4% during that session.
Argus tracked a trough of -3.7% from its starting point during tracking.
Our momentum scanner triggered 10 alerts that day, indicating notable trading interest and price volatility.
The June 26 inducement-award announcement was followed by a -3.02% 24-hour reaction, while the June ...
Analysis
The June 26 inducement-award announcement was followed by a -3.02% 24-hour reaction, while the June 11 counterpart was followed by 0.57%. The current grant terms add no operating results; the active S-3 shelf and high short positioning remain relevant context.
Key Figures
Aggregate Options:52,500 sharesRecipients:2 employeesApproval Date:July 22, 2026+4 more
7 metrics
Aggregate Options52,500 sharesGranted to two non-executive employees
"approved the grant of options to purchase an aggregate of 52,500 shares"
Equity inducement awards are special stock-based rewards given to new employees to encourage them to join a company or stay long-term. They are like signing bonuses paid with company shares instead of cash, helping motivate employees to contribute to the company's success.
nasdaq listing rule 5635(c)(4)regulatory
"in accordance with Nasdaq Listing Rule 5635(c)(4)"
NASDAQ Listing Rule 5635(c)(4) is a rule that requires a company to get approval from its shareholders before selling a large amount of its shares, usually over 20%. This helps protect investors by making sure the company doesn't flood the market with new shares without their say, which could lower the stock's value.
exercise pricefinancial
"an exercise price equal to $15.83"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
vestingfinancial
"shall vest and become exercisable as to one-fourth"
Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.
WALTHAM, Mass., July 23, 2026 (GLOBE NEWSWIRE) -- Crescent Biopharma, Inc. (“Crescent” or the “Company”) (Nasdaq: CBIO), a clinical-stage biotechnology company dedicated to rapidly advancing the next wave of therapies for cancer patients, today announced that the independent Compensation Committee of its Board of Directors approved the grant of options to purchase an aggregate of 52,500 shares of the Company’s ordinary shares to two non-executive employees as equity inducement awards under the Crescent Biopharma, Inc. 2025 Employment Inducement Incentive Award Plan, as amended (the “Inducement Plan”). The options were approved on July 22, 2026 and were material to each employee's acceptance of employment with Crescent, in accordance with Nasdaq Listing Rule 5635(c)(4).
The options were granted with a 10-year term and an exercise price equal to $15.83, the closing price per share of Crescent’s ordinary shares as reported by Nasdaq on July 22, 2026. The options granted to each employee shall vest and become exercisable as to one-fourth (1/4th) of the shares subject to the respective options on the first anniversary of the employee’s start date, and one-forty-eighth (1/48th) of the shares subject to the respective options shall vest and become exercisable monthly thereafter, in each case, subject to continuous service with Crescent through the applicable vesting dates. The options are subject to the terms of the Inducement Plan and the terms and conditions of an option agreement covering the applicable grant.
About Crescent Biopharma
Crescent Biopharma’s vision is to build a world leading oncology company bringing the next wave of therapies for cancer patients. The Company’s clinical-stage pipeline includes its lead program, a PD-1 x VEGF bispecific antibody, as well as novel antibody-drug conjugates (ADCs). By leveraging multiple modalities and established targets, Crescent aims to rapidly advance potentially transformative therapies as single agents and as part of combination regimens to treat a range of solid tumors. For more information, visit www.crescentbiopharma.com and follow the Company on LinkedIn and X.
What equity inducement awards did Crescent Biopharma (CBIO) grant on July 22, 2026?
Crescent Biopharma granted options to purchase an aggregate of 52,500 ordinary shares to two non-executive employees. According to Crescent Biopharma, these were equity inducement awards under its 2025 Employment Inducement Incentive Award Plan, approved by the Board’s Compensation Committee.
What is the exercise price and term of Crescent Biopharma (CBIO) inducement stock options?
The inducement stock options have an exercise price of $15.83 per share and a 10-year term. According to Crescent Biopharma, the price equals the July 22, 2026 Nasdaq closing price of its ordinary shares.
How do the Crescent Biopharma (CBIO) inducement options vest for the new employees?
The options vest 25% on the first anniversary of each employee’s start date, then monthly thereafter. According to Crescent Biopharma, one-forty-eighth of the shares vest monthly over the remaining three years, subject to continuous service.
Why were the Crescent Biopharma (CBIO) stock options granted as inducement awards?
The options were granted as equity inducement awards material to each employee’s acceptance of employment. According to Crescent Biopharma, the grants comply with Nasdaq Listing Rule 5635(c)(4) under its 2025 Employment Inducement Incentive Award Plan.
How many Crescent Biopharma (CBIO) shares are covered by each employee’s inducement option grant?
Crescent Biopharma granted options over an aggregate of 52,500 shares to two employees, implying each received a portion of this total. According to Crescent Biopharma, all options are granted under the 2025 Employment Inducement Incentive Award Plan.
What conditions apply to exercising Crescent Biopharma (CBIO) inducement stock options?
The options must be vested and are exercisable within a 10-year term at $15.83 per share. According to Crescent Biopharma, vesting requires continuous service and is subject to the Inducement Plan and individual option agreements.
